MULTIQURE
Research MULTIQURE (MQR.WA) on Bullrun: market cap PLN 363.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMQR.WA
- ExchangeXWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 363.46M
- Financial periodQ1 2026
- RevenuePLN 0
- Net income-PLN 2.24M
- Free cash flow-PLN 3.17M
Valuation Snapshot
latest market cap is PLN 363.46M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | PLN 363.46M | n/a | n/a | n/a |
About MULTIQURE
MultiQure S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MULTIQURE's market cap?
MULTIQURE's market capitalization is PLN 363.46M.
What does MULTIQURE do?
MultiQure S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026. The company was founded in 2010 and is based in Wroclaw, Poland.